English

RLS GLOBAL AB (PUBL) INTERIM REPORT, Q2, 2020

Report this content

APRIL 1st - JUNE 30th

  • Net sales amounted to TSEK 739 (TSEK 464)
  • Earnings before interest and taxes (EBIT) amounted to MSEK -5,6 (MSEK -5,8)
  • Earnings per share before dilution at SEK -0,09 (SEK-0,02)
  • Cash flow from operating activities amounted to MSEK -5,5 (MSEK-6,3)
  • Liquid assets at the end of the period MSEK 30,3 (MSEK 8,3)
  • Equity ratio was 91 % (82 %)

JANUARY 1st - JUNE 30th

  • Net sales amounted to MSEK 1,1 (MSEK 0,7)
  • Earnings before interest and taxes (EBIT) amounted to MSEK -9,5 (MSEK-11,6)
  • Earnings per share before dilution at SEK -0,14 (SEK -0,20)
  • Cash flow from operating activities amounted to MSEK -10,9 (MSEK -11,8)
  • Liquid assets at the end of the period MSEK 30,3 (MSEK 8,3)
  • Equity ratio was 91 % (82 %)

SUMMARY OF EVENTS DURING SECOND QUARTER

  • AGM was held on May 26
  • RLS Global AB has signed an agreement with Region Stockholm and Gotland for ChloraSolv  
  • A successful launch in the Region of Kalmar - RLS now see that the purchase of ChloraSolv reappears with several users
  • RLS has established a collaboration with Cardiff University UK and Bispebjerg Hospital Denmark and tests will start in August / September

SUMMARY OF EVENTS AFTER SECOND QUARTER

  • The ChloraSolv01 study is closed, the first results have been received by RLS. Scientific report will be compiled by chief examiner Jan Apelqvist

COVID-19

  • In the current situation, the Board has considered the impact of different possible future COVID-19 related scenarios
  • Because the healthcare sector is so extremely strained under the prevailing circumstances, all processes take longer which affects our market penetration and other activities, resulting in RLS focusing even more on R&D projects
  • There is an increased interest in CariSolv due to the result of the transition in the dental industry from procedures that generate aerosol to chemo-mechanical treatments

Trading place and Certified Advisor
RLS Global’s shares has been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Advisor is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. During the period 2012 - 2017, the company was listed on Aktietorget.

Contact information
Karin Fischer, CEO
E-mail: karin.fischer@rlsglobal.se
Telephone: +46 702-48 46 51

Eva Jagenheim, CFO
E-mail: eva.jagenheim@rlsglobal.se
Telephone: +46 31 780 68 20

The Interim Report Q2, 2020 is enclosed and is also available at www.rls.global

Publication
RLS Global AB (publ) is obliged to make the information contained herein public pursuant to the EU market abuse regulation. The information was submitted for publication through the agency of the above contact person, at 09.00 CET on July 17th, 2020.

About RLS Global AB
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS Global develop product within wound care. RLS Global has a portfolio of strong brands, including ChloraSolv® and Carisolv®. The company is listed on Nasdaq First North Growth Market with Redeye Aktiebolag as the Certified Advisor,
phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. Read more at www.rls.global

Subscribe

Documents & Links